See more : Aduro Clean Technologies Inc. (ACTHF) Income Statement Analysis – Financial Results
Complete financial analysis of Innate Pharma S.A. (IPHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Innate Pharma S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- UnipolSai Assicurazioni S.p.A. (US.MI) Income Statement Analysis – Financial Results
- NeurAxis, Inc. (NRXS) Income Statement Analysis – Financial Results
- Martin Midstream Partners L.P. (MMLP) Income Statement Analysis – Financial Results
- Azarga Metals Corp. (EUUNF) Income Statement Analysis – Financial Results
- Zhejiang Lianxiang Smart Home Co., LTD (603272.SS) Income Statement Analysis – Financial Results
Innate Pharma S.A. (IPHA)
About Innate Pharma S.A.
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.90M | 49.64M | 12.11M | 56.83M | 68.97M | 79.89M | 32.63M | 56.16M | 17.91M | 907.00K | 12.47M | 10.38M | 11.74M | 4.32M | 7.72M | 12.92M | 14.29M | 6.20M | 1.30M |
| Cost of Revenue | 56.02M | 51.66M | 47.00M | 3.04M | 45.16M | 69.56M | 67.00M | 48.63M | 29.91M | 12.09M | 7.58M | 6.86M | 1.64M | 3.43M | 3.35M | 2.56M | 2.77M | 2.20M | 944.00K |
| Gross Profit | -4.12M | -2.02M | -34.89M | 53.79M | 23.82M | 10.34M | -34.37M | 7.53M | -12.00M | -11.18M | 4.89M | 3.51M | 10.10M | 893.00K | 4.37M | 10.37M | 11.52M | 3.99M | 356.00K |
| Gross Profit Ratio | -7.94% | -4.08% | -288.08% | 94.65% | 34.53% | 12.94% | -105.33% | 13.41% | -67.02% | -1,232.64% | 39.22% | 33.86% | 86.05% | 20.67% | 56.62% | 80.21% | 80.64% | 64.47% | 27.38% |
| Research & Development | 56.02M | 51.66M | 47.00M | 58.61M | 1.60M | 69.56M | 67.00M | 48.63M | 29.91M | 22.67M | 15.13M | 13.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.75M | 14.47M | 15.99M | 31.25M | 40.73M | 18.14M | 15.66M | 8.88M | 5.59M | 12.50M | 10.38M | 9.33M | 0.00 | 6.27M | 8.52M | 0.00 | 0.00 | 1.64M | 938.00K |
| Selling & Marketing | 0.00 | 7.96M | 9.53M | -861.00K | 8.85M | 1.11M | 527.00K | 450.00K | 288.00K | 314.00K | 283.00K | 406.00K | 9.79M | 7.06M | 10.06M | 0.00 | 0.00 | 207.00K | 139.00K |
| SG&A | 11.75M | 22.44M | 25.52M | 30.39M | 49.58M | 19.25M | 16.18M | 9.33M | 5.88M | 12.82M | 10.67M | 9.73M | 9.79M | 7.06M | 10.06M | 0.00 | 0.00 | 1.84M | 1.08M |
| Other Expenses | -3.20M | -8.04M | -12.59M | -13.62M | -309.00K | -14.06M | -10.57M | -9.37M | -7.11M | -19.00K | 179.00K | 2.00K | 7.88M | 32.00K | 909.00K | 21.37M | 20.62M | 9.34M | 5.69M |
| Operating Expenses | 64.57M | 66.06M | 59.94M | 75.38M | 50.87M | 74.75M | 72.61M | 48.59M | 28.68M | 8.76M | 7.66M | 6.88M | 17.67M | 14.58M | 19.90M | 21.37M | 20.62M | 11.18M | 6.77M |
| Cost & Expenses | 64.57M | 66.06M | 59.94M | 75.38M | 96.03M | 74.75M | 72.61M | 48.59M | 28.68M | 20.85M | 15.24M | 13.75M | 19.31M | 18.01M | 23.25M | 23.93M | 23.38M | 13.38M | 7.72M |
| Interest Income | 3.18M | 4.78M | 6.34M | 4.86M | 1.62M | 1.58M | 1.25M | 0.00 | 27.00K | 445.00K | 244.00K | 34.00K | 945.00K | 541.00K | 0.00 | 1.19M | 212.00K | 1.20M | 280.00K |
| Interest Expense | 640.00K | 5.32M | 4.00M | 6.76M | 204.00K | 102.00K | 113.00K | 124.00K | 139.00K | 0.00 | 0.00 | 225.00K | 520.00K | 509.00K | 0.00 | 36.00K | 39.00K | 2.00K | 0.00 |
| Depreciation & Amortization | 5.09M | 4.42M | 4.57M | 9.39M | 16.53M | 7.40M | 4.40M | 3.26M | 2.66M | 2.34M | 880.00K | 839.00K | 901.00K | 1.10M | 1.02M | 539.00K | 536.00K | 298.00K | 301.00K |
| EBITDA | -1.84M | -61.30M | -43.23M | 43.11M | -20.86M | -3.30M | -35.65M | 10.83M | -8.09M | -17.14M | -1.91M | -1.76M | -5.80M | -12.32M | -14.47M | -12.48M | -8.50M | -6.94M | -6.11M |
| EBITDA Ratio | -3.54% | 68.00% | -304.53% | 75.85% | -12.88% | 15.48% | -109.25% | 20.73% | -45.18% | -1,967.81% | -17.70% | -27.62% | -47.19% | -291.44% | -187.48% | -80.99% | -59.51% | -91.90% | -448.31% |
| Operating Income | -12.67M | -11.65M | -47.83M | -13.69M | -27.05M | 5.15M | -39.98M | 7.57M | -10.77M | -19.97M | -2.79M | -3.39M | -7.57M | -13.69M | -15.54M | -11.01M | -9.09M | -7.24M | -6.42M |
| Operating Income Ratio | -24.41% | -23.47% | -394.86% | -24.09% | -39.22% | 6.44% | -122.53% | 13.48% | -60.16% | -2,201.32% | -22.40% | -32.63% | -64.48% | -316.90% | -201.33% | -85.16% | -63.62% | -116.85% | -493.46% |
| Total Other Income/Expenses | 5.10M | -547.00K | 2.35M | -15.53M | 6.29M | -2.43M | -8.03M | 5.37M | 4.07M | 319.00K | -99.00K | 183.00K | 590.00K | 32.00K | 909.00K | 1.15M | 173.00K | 1.20M | 286.00K |
| Income Before Tax | -7.57M | -57.97M | -45.48M | -63.98M | -20.76M | 2.72M | -48.02M | 12.94M | -6.71M | -19.65M | -2.89M | -3.20M | -6.98M | -13.66M | -14.63M | -9.85M | -8.92M | -6.04M | -6.13M |
| Income Before Tax Ratio | -14.59% | -116.79% | -375.48% | -112.58% | -30.10% | 3.40% | -147.15% | 23.04% | -37.45% | -2,166.15% | -23.19% | -30.83% | -59.45% | -316.16% | -189.55% | -76.23% | -62.41% | -97.53% | -471.46% |
| Income Tax Expense | 0.00 | 41.13M | 13.66M | 6.76M | 206.00K | -333.00K | 368.00K | 301.00K | 139.00K | -24.00K | -51.00K | -146.00K | 1.13M | 0.00 | 46.00K | 0.00 | 51.00K | 1.20M | 286.00K |
| Net Income | -7.57M | -99.10M | -59.14M | -70.75M | -20.97M | 3.05M | -48.39M | 12.64M | -6.71M | -19.65M | -2.89M | -3.20M | -6.98M | -13.66M | -14.63M | -9.85M | -8.92M | -6.04M | -6.13M |
| Net Income Ratio | -14.59% | -199.65% | -488.24% | -124.48% | -30.40% | 3.82% | -148.28% | 22.51% | -37.45% | -2,166.15% | -23.19% | -30.83% | -59.45% | -316.16% | -189.55% | -76.23% | -62.41% | -97.53% | -471.46% |
| EPS | -0.09 | -1.24 | -0.74 | -0.90 | -0.31 | 0.05 | -0.89 | 0.23 | -0.13 | -0.39 | -0.07 | -0.08 | -0.19 | -0.36 | -0.56 | -0.38 | -0.36 | -0.34 | -0.41 |
| EPS Diluted | -0.09 | -1.24 | -0.74 | -0.90 | -0.31 | 0.05 | -0.89 | 0.23 | -0.13 | -0.39 | -0.07 | -0.08 | -0.19 | -0.36 | -0.56 | -0.38 | -0.36 | -0.34 | -0.41 |
| Weighted Avg Shares Out | 80.45M | 79.64M | 79.54M | 78.93M | 66.91M | 58.78M | 54.35M | 53.87M | 51.58M | 50.15M | 38.70M | 37.80M | 37.69M | 37.44M | 26.30M | 25.67M | 25.08M | 17.77M | 14.90M |
| Weighted Avg Shares Out (Dil) | 80.45M | 79.64M | 79.54M | 78.93M | 66.91M | 58.78M | 54.35M | 53.87M | 53.40M | 50.15M | 38.70M | 37.80M | 37.69M | 37.44M | 26.30M | 25.67M | 25.08M | 17.77M | 14.90M |
Innate Pharma Reports First Half 2023 Financial Results and Business Update
Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update
Innate Pharma to Participate in Upcoming Investor Conference
First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag
Why Shares of Innate Pharma Jumped Thursday
Source: https://incomestatements.info
Category: Stock Reports